From: Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
Virus name, type and strain | Virus short name | Viral gene modification | Non-viral gene addition | Cell culture, mouse, human | Tumor type | Virus administration route, dose, times | Combination therapy | Safety (Major AEs) | Efficacy, (Tumor size, Survival benefit) | Novelty, advantages | Comments, disadvantages | Refs |
---|---|---|---|---|---|---|---|---|---|---|---|---|
HSV-1 | oHSV-1 |  |  | 6 to 8-week-old NOD. Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice | Breast cancer, brain cancer, BCBMs | Intracranially infused with EGFR-CAR NK-92, oHSV-1, NK-92-EV | EGFR-CAR NK-92 cells |  | Suppression of tumor growth and significantly longer survival | Optimal efficacy in patients with EGFR + tumor |  | [36] |
HSV-1 | UV-HSV-1 |  |  | NRG-3GS mice (15 weeks) | leukemia | 3 × 106 human PBMCs + 0.1 pfu/PBMC for 16 h | IL-15 |  | Prolonged survival of T cell-depleted PBMCs mice | Herpesviridae members are potent stimulators of innate immune function | Future allogeneic mononuclear cell or NK infusion | [37] |
HSV-1 | oHSV-1 | Â | Â | Female athymic nu/nu mice | GBM | IP, with PBS/ bortezomib (0.8Â mg/kg) twice a week | Bortezomib | Â | Necrosis in tumors | NK cell adjuvant therapy, virotherapy and proteasome blockade | Toxicities may be discovered | [155] |
HSV | oHSV, MG18L | Â | Â | PARPi-sensitive or -resistant GSC. Female athymic mice | GBM | IP, olaparib (50Â mg/kg) or vehicle; IT, MG18L or PBS | PARPi, Olaparib | Â | Greatly extended survival | Applicable not only to GBM, but also to other tumor types | Treatment schedule not optimized | [33] |
HSV | MG18L |  |  | 7–8-week-old female SCID mice | GBM | Galunisertib (100 mg/kg), oral gavage daily from day 7 to 16. IT, MG18L (1 × 106 pfu/3 µl) on day 9 | TβR inhibitors SB431542, galunisertib |  | Cures in 60% of mice bearing orthotopic recurrent GBM | A novel synergistic interaction of oHSV therapy and TGF-β signaling blockade | Effect for initiating poorly invasiveGBM | [156] |
HSV-1 | oHSV | Â | Â | Mouse model of ATC | PDTC ATC | A single injection into the tumor using a Hamilton syringe | 40Â mg/kg of BRAFi (PLX4720) by oral gavage daily | Â | Tumor reduced by 50% and inflammatory | Activated NK and T cells, and successfully incorporated anti-CTLA-4 or anti-PD-1 | Â | [157] |
HSV | oHSV | γ1-34.5 deleted |  | 6- 8-week-old C57BL/6 mice | MPNSTs | C134 (3.5 × 107 in 100 μL 10% glycerol in PBS) IT on day 4 and a week later | 3 doses of RUX (INCB018424, AbexBio; 60 mg/kg) daily IP |  | Antitumor antigen and an antiviral responses | CD8 + T cell activation indispensable for the antitumor benefit | CTL response not been fully investigated | [31] |
HSV | oHSV |  | Vstat120, anti-angiogenic | Female BALB/C mice or Bai1 wildtype or knockout C57/Bl/6 mice (littermates) | GBM | IT, HBSS/PBS, rHSVQ1, or RAMBO virus (1 × 105 PFU/mouse) |  | Transient weight loss | Reduced macrophages/microglia, increased virus replication | Shielded from inflammatory macrophage antiviral response, without reducing safety | How Vstat12 blocks BAI1 unclear | [39] |
HSV | oHSV-TRAIL |  | TRAIL | Athymic mice (6 weeks of age); TMZ-resistant primary and recurrent GSC | GBM | IT, 3–6 μl, 2.0 × 106 pfu, twice on days 14 and 26 |  |  | Prolong survival through robust apoptosis | Potent therapeutic efficacy |  | [158] |
HSV | MSC-oHSV |  | MSCs | a BRAF mutant line from BrafV600E/wtCdkn2A−/−Pten−/− mice | Melanoma | ICA, intracarotid injection | PD-L1 blockade |  | Significantly prolongs the survival | Target melanoma brain metastasis |  | [72] |
HSV-1 | oHSV-1- SU4-124 | ICP4 under survivin promoter | Rat FGF2 5’UTR in front of ICP4 ORF | Female C57BL6 mice | Glioma U87 | IT, 100 mm3 tumor, 3galΔ3, or CMV-ICP4 HSV-1 or SU4-124 HSV-1 |  |  | a significantly enhanced antitumor effect | Triple-regulated ICP4 gene expressed from an amplicon to supplement a replication-defective HSV-1 |  | [38] |
HSV | oHSV- G47Δ | G47Δ-mCherry, G47Δ-Us11-fluc | G47Δ | MN3 cells, 7–8-week-old female SCID mice | Meningiomas | IT, 2 G47Δ injections (2 × 106 pfu/3 µL) |  |  | Significantly prolonged survival | Efficacy against several patient-derived meningioma lines of different grade | To study MN3 as CSC | [159] |
HSV | oHSVG47Δ(G47Δ-mIL12) | G47Δ | IL-12 | Female C57Bl/6 mice (8–9 weeks) | GBM | IT, G47Δ-mIL12 in 2 μl | Anti-CTLA-4, anti-PD-1 |  | 89% long-term survivors; the cure rate 4/6 and 5/7 | Synergistic effect and inducing immunological memory | Lack of representative murine models | [32] |
Ad | oAd- CARsc-pSia |  | Bispecific adapter CARsc-pSia | C57BL/6 and NMRI-nu/nu mice | SCLC | IV pretreated with CARsc-pSia (15 μg/250 μL/mouse) or PBS | hTERT-AdLuc (1 × 109 pfu/mouse) | None | Tumor regression,prolonged survival, but not in T-cell-deficient mice | Effective retargeting elicits an effective tumor-directed T-cell response |  | [41] |
Ad | ICOVIR-15 K | BiTA under major late promoter | ICOVIR-15 K-cBiTAto EGFR | 8-week-old female SCID/beige mice | Lung cancer A549, Colon cancer HCT116 | A549 tumors, IV 2 × 109 VP; HCT116 tumors, IV 1 × 1010 VP |  |  | Enhances antitumor efficacy in vivo | OV-BiTA can overcome key limitations | Oncolytic properties reduced twofold | [43] |
Ad | EnAd | Â | BiTA to EpCAM | HEK293A, DLD, SKOV3, MCF7, A431, A549, NHDF and PC3, CHO | Multiple cancers | Cells incubated in 50% exudate in 500Â ng/ml BiTA or 100Â vp/cell EnAd | Â | Â | A marked cancer cell depletion | A new treatment of disseminated cancer | Â | [101] |
Ad | NSC.CRAd-S-pk7 |  | NSC. Survivin promotor, a poly-L-lysine (pk7) |  | Ovarian cancer mice model | 3 weeks of 1 × 106 cells [5 × 108 pfu]/day | Cisplatin | Not significantly worsen toxicity by daily score | More substantial decreases in omental tumor burden | Increased efficacy with no added toxicity | Its replication is conditional upon overexpression of survivin | [84] |
Ad | DNX-2401 (Delta-24-RGD; tasadenoturev) | a 24 bp deletion in E1A | RGD-motif into the fiber H-loop | DIPG and pHGG cell lines | pHGG/DIPG mice model | Delta-24-RGD (108 pfu/animal) intracranially 1 or 3 times in 3–4 μl 3 days later |  | No adverse effect | Increased survival by an average of 40 days (P = 0.024, Log-rank test) | Therapeutic option for pHGG and DIPG |  | [42] |
Ad | oAd-MSCs |  |  | BALB/c mice | Renal adenocarcinoma, melanoma | 2 × 106 DiR-labeled oAd-MSCs per mouse, IP injected |  |  | Tumors decrease by 50% and inflammatory | TAMS and NK infiltrated, and TIL changed |  | [40] |
VV | EphA2-TEA-VV |  | EphA2-TEA | SCID Beige mice; A549 cells | NSCLC | IP injection, 1 × 108 pfu | PBMCs | None | Significant tumor growth decrease | The EphA2-TEA-VVs activated human PBMCs |  | [47] |
VV | VVDD | hSNF5 |  | CB17 SCID mice | AT/RT | 50 μl VVDD-hSNF5 or VVDD GFP |  |  | Significant tumor regression | Cell cycle arrest and proliferation inhibit |  | [160] |
MV | MV-H |  | DARPins | 6- to 12-week-old female Hsd: Athymic Nude-Foxn1nu mice | ovarian carcinoma | IP four times, 2 × 106 TCID50/injection |  |  | The tumor burden reduced by 76% (MV-Ec4-Pro9-G3) to 95% (MV-Ec4) | harbor an intrinsic and robust specificity for heterogeneous tumor cells | DARPin/HER2 interaction inhibitsvirus spread | [48] |
MV | MV-BiTA | Â | MV-eGFP-mCD3xCEA | C57BL/6Â J mice | Primary human colorectal cancer | intra-/peritumoral injection, 106 pfu in 100Â mL | BiTA to CEA | Â | Increased T-cell infiltration and activation | Tumor-restricted continuous BiTA expression and in situ vaccination effects | OVs comparison lacking | [100] |
Arenavirus | LCMV |  |  | MOPC-tumur-bearing C57BL/6 mice | Colon cancer, melanoma, hepatocellular carcinoma | 2 × 104 PFU peritumourally or 2 × 106 PFU IV | CD8+ T cells; PD-1 blockade |  | Increased local and splenic virus propagation for more than 30 days | Effective tumor treatment | Not known in humans | [161] |
Rhabdovirus | MG1 |  | eGFP tagged Maraba | S180; 6 week old female Balb/C mice | Sarcoma | IT, 3 doses MG1 (1 × 108 pfu/mouse) at days 8, 10 and 13 |  |  | Eradication of 80% of tumors and protection from re-challenge | MG1 based oncolytic immunotherapy |  | [162] |
NDV | NDV-ICOSL |  | NDV-ICOSL | Mice | B16-F10 melanoma | On days 7, 10, 13 and 16, IT, 100 μl of 2 × 107 pfu | Anti-CTLA-4 |  | Enhanced T cells infiltration and anti-tumor effect | A strong rationale for clinical evaluation | Mechanism not known. Subset patients | [108] |
Canine virus serotype 2 | ICOCAV17 | E1ΔD21 | human PH20 hyaluronidase (PH20) | Dogs | Spontaneous tumors | dCelyvir administered over 45 min through a peripheral or central venous line at 0.5 × 106 cells/kg | i.v. with metilprednisone 1 mg/kg, metamizol 30, difenhidramine 0.5 | 27% (4) show clinical AE | 74% response rate, 14.8% complete responses | OV-MSC represents an effective cancer therapy | Hyaluronidase for EMC | [44] |
Coxsackievirus | CVA21 | Â | Â | Peripheral blood mononuclear cells | AML MM | The PBMC exposed to CVA21 for 24Â h | Â | Â | CVA21 stimulated potent anti-tumor immunity | AML cells resistant oncolysis, immune- killing of MM/AML observed | Â | [163] |
Myxoma virus | MYXV |  | IL-15 complex with a subunit of its receptor and tdTR | 6–8-week-old C57BL/6 female mice | Melanoma | Injected (day 9) with a single dose of MSCs (5 × 105/100 mL PBS) |  |  | Marked regression of lesions and could increase survival | MSCs ferrying MYXV to pulmonary melanoma foci triggering immune effects |  | [83] |
Bovine pestivirus | BVDV | Â | Â | NOD-SCID mice | MM | IT twice a week for 2Â weeks | bortezomib | Â | significantly reduced tumor burden | BVDV has direct oncolytic effect in myeloma | Â | [164] |
Zika virus | ZIKV-Dakar | a 10-nt deletion in the 3’ UTR |  | C57BL6/J mice, 4 × 104 GL261 or CT2A glioma cells | GBM | IT, mouse-adapted ZIKV (105 FFU) | Anti-PD-1, IP on days 8, 10, 12, and 14, 10 mg/kg |  | Combination therapy improved long-term survival to 80% |  | Optimization of the timing of ZIKV administration | [27] |